Literature DB >> 21955141

The Bcl-2/Bcl-XL inhibitor ABT-737 promotes death of retinoblastoma cancer cells.

Nathalie Allaman-Pillet1, Anne Oberson, Francis Munier, Daniel F Schorderet.   

Abstract

PURPOSE: Retinoblastoma is a malignant tumor that usually develops in early childhood. During retinoblastoma spreading, RB1 gene inactivation is followed by additional genomic modifications which progressively lead to resistance of tumor cells to death. Drugs that act at downstream levels of death signaling pathways should therefore be interesting in killing retinoblastoma cells. ABT-737, a BH3 mimetic molecule effective at the mitochondrial level, has been shown to induce apoptosis in different human tumoral cell lines as well as in primary patient-derived cells, and in a mouse xenograph model.
METHODS: In this report, we analyzed the pro-death effect of ABT-737 on two human retinoblastoma cell lines, Y79 and WERI-Rb, as well as on the mouse photoreceptor cell line 661W.
RESULTS: We observed that ABT-737 was very effective as a single agent in inducing human WERI-Rb cells apoptosis without affecting the mouse 661W photoreceptor cells. However human Y79 cells were resistant to ABT-737, as a probable consequence of the absence of Bax. The high sensitivity of WERI-Rb to ABT-737 can be increased by downregulating Mcl-1 using the proteasome inhibitor MG-132. Preliminary analysis in primary mouse retinoblastoma tumoral cell lines predicts high sensitivity to ABT-737.
CONCLUSION: Our data suggest that ABT-737 or related compounds could be a highly effective drug in the treatment of some retinoblastomas.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21955141     DOI: 10.3109/13816810.2011.615077

Source DB:  PubMed          Journal:  Ophthalmic Genet        ISSN: 1381-6810            Impact factor:   1.803


  8 in total

1.  Norcantharidin combined with ABT-737 for hepatocellular carcinoma: Therapeutic effects and molecular mechanisms.

Authors:  Jing Ren; Gang Li; Wen Zhao; Ling Lin; Tao Ye
Journal:  World J Gastroenterol       Date:  2016-04-21       Impact factor: 5.742

2.  Lentivirus-Mediated Knockdown of Astrocyte Elevated Gene-1 Inhibits Growth and Induces Apoptosis through MAPK Pathways in Human Retinoblastoma Cells.

Authors:  Ying Chang; Bin Li; Xiaolin Xu; Ling Shen; Haixia Bai; Fei Gao; Zhibao Zhang; Jost B Jonas
Journal:  PLoS One       Date:  2016-02-19       Impact factor: 3.240

Review 3.  BH3-mimetics: recent developments in cancer therapy.

Authors:  Paul A Townsend; Maria V Kozhevnikova; Olivier N F Cexus; Andrey A Zamyatnin; Surinder M Soond
Journal:  J Exp Clin Cancer Res       Date:  2021-11-09

Review 4.  Programmed cell death, redox imbalance, and cancer therapeutics.

Authors:  Xiaofeng Dai; Danjun Wang; Jianying Zhang
Journal:  Apoptosis       Date:  2021-07-08       Impact factor: 4.677

5.  A decision process for drug discovery in retinoblastoma.

Authors:  María Belen Cancela; Santiago Zugbi; Ursula Winter; Ana Laura Martinez; Claudia Sampor; Mariana Sgroi; Jasmine H Francis; Ralph Garippa; David H Abramson; Guillermo Chantada; Paula Schaiquevich
Journal:  Invest New Drugs       Date:  2020-11-16       Impact factor: 3.850

6.  The sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activity.

Authors:  Ryan C Thompson; Iosif Vardinogiannis; Thomas D Gilmore
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

7.  Preferential targeting of cancer stem cells in the radiosensitizing effect of ABT-737 on HNSCC.

Authors:  Marion Gilormini; Céline Malesys; Emma Armandy; Patrick Manas; Jean-Baptiste Guy; Nicolas Magné; Claire Rodriguez-Lafrasse; Dominique Ardail
Journal:  Oncotarget       Date:  2016-03-29

8.  Chemoinformatic Screening for the Selection of Potential Senolytic Compounds from Natural Products.

Authors:  Oscar Salvador Barrera-Vázquez; Juan Carlos Gómez-Verjan; Gil Alfonso Magos-Guerrero
Journal:  Biomolecules       Date:  2021-03-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.